Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep …
Full VVOS analysis →
Competitive advantage assessment
Key strengths
Durable Revenue GrowthRevenue growth trend is strong (score 0.68). Durable top-line expansion confirms the razor-and-blade flywheel is working.
Key risks
Weak Capital Return ProfileCapital return quality is below peers (score 0.06). Low ROIC raises questions about M&A discipline and pipeline ROI.
Weak FCF GenerationFCF margin quality lags peers (score 0.32). Below-peer FCF conversion is a MedTech quality warning.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Vivos Therapeutics, Inc. ranks #127 of 160
scored companies in Medical Devices by moat score — the top 79%.
The widest moat in the group is iRadimed Corporation (IRMD)
at 83/100.
Moat scores for companies ranked near VVOS in Medical Devices
How VVOS scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 45
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 5
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 25
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 43
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Not measurable
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 45
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Vivos Therapeutics, Inc. (VVOS) scores 31 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #127 of 160 scored companies in Medical Devices, the top 79%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Pricing Power & Consumable Moat (45/100) and its weakest is R&D Pipeline & Capital Returns (5/100).
How does Vivos Therapeutics, Inc. compare with other Medical Devices companies?
Vivos Therapeutics, Inc. ranks #127 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are IceCure Medical Ltd. (ICCM) at 32 just above it and Modular Medical, Inc. (MODD) at 30 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.
Why is Vivos Therapeutics, Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Vivos Therapeutics, Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and VVOS scores: Pricing Power & Consumable Moat (45), R&D Pipeline & Capital Returns (5), FCF Quality & Cash Conversion (25), Commercial Execution (43), Capital Structure & Resilience (not measurable), Growth Durability (45). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.